Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease.

Barakat HE, Abougalambou AS, Maher W, Nour SM, Abdelhalim IT, Binsaleh AY, Belal DMI, Abougalambou SS

DOI: 10.3389/fphar.2026.1870914
Published: 2026
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1870914,
  title = {Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease.},
  author = {Barakat HE and Abougalambou AS and Maher W and Nour SM and Abdelhalim IT and Binsaleh AY and Belal DMI and Abougalambou SS},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1870914},
  url = {https://doi.org/10.3389/fphar.2026.1870914}
}

RIS

TY  - JOUR
TI  - Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease.
AU  - Barakat HE
AU  - Abougalambou AS
AU  - Maher W
AU  - Nour SM
AU  - Abdelhalim IT
AU  - Binsaleh AY
AU  - Belal DMI
AU  - Abougalambou SS
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1870914
UR  - https://doi.org/10.3389/fphar.2026.1870914
ER  -

APA

HE, B., AS, A., W, M., SM, N., IT, A., AY, B., DMI, B., & SS, A. (2026). Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1870914

Source records

pubmed · retrieved 2026-09-24T22:57:53.799Z